A Phase 2a, randomized, double-blind, placebo-controlled study of oral FXR modulator EYP001a combined with nucleos(t)ide analogues (NA) in virologically suppressed chronic hepatitis B patients to improve functional cure rates
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs EYP 001 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors ENYO Pharma
- 19 Sep 2019 According to an ENYO Pharma media release, the company expects to report data from this trial in the second half of 2020.
- 04 Jun 2018 According to an ENYO Pharma media release, completed a 40 million euro Series B financing from the US and European investors which will be used to support this trial.
- 05 Mar 2018 New trial record